Current Research Trials

Oncology Clinical Trials

Registry and Biology Protocols

  • Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study:
  • Neuroblastoma Biology Studies
  • Renal Tumors Classification, Biology and Banking Study
  • NCI COVID-19 in Cancer Patients Study NCCAPS: A Longitudinal Natural History Study

Acute Lymphoblastic Leukemia (ALL) Protocols

  • Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
  • International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
  • A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
  • A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly -HR-BALL Post Consolidation Therapy

Acute Myeloid Leukemia (AML) Protocols

  • Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Central Nervous System (CNS) Protocols

  • A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
  • A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
  • A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
  • A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) – CIRB activated

Hodgkins Disease Protocols

  • A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma)

Non-Sarcoma Solid Tumor Protocols

  • A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
  • Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
  • A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
  • A Randomized Phase 2 Trial of Axitinib/Nivolumab combination therapy vs single agent Axitinib or Nivolumab for the
    treatment of TFE/Translocation Renal Cell Carcinoma across all age groups

Sarcoma Protocols

  • A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Cancer Control and other Non-Therapeutic Protocols

  • Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
  • A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated Asparaginase.
  • Umbrella Long-Term Follow-Up Protocol
  • Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
  • Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
  • LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
  • A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer
  • Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma –
  • Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
  • Work Ability in Young Adult Survivors (WAYS)
  • Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices

Molecular and Pharmacokinetic Protocols

  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice Master Version) Screening Protocol
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions.
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of LY3023414 in Solid Tumors
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
  • NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice Master Version) Control Document
    A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies
  • A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating The Safety Toleraility, Pharmacokinetics, And Preliminary Activity of Idasanutlin Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemias or Solid Tumors

For More Information

  • Phone:  (210) 562 – 9149
  • Email:  PhoResearchOffice@uthscsa.edu